Other · Immune activation · developed by Protara Therapeutics
TARA-002 is a lyophilized preparation of killed, penicillin-treated group A Streptococcus pyogenes (Su strain) given intravesically as an immunostimulant. It is studied in non-muscle invasive bladder cancer, including bladder carcinoma in situ.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07480356 | Phase 3 | Bladder (Urothelial, Transitional Cell) Cancer | Recruiting | TARA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder (Urothelial, Transitional Cell) CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituNon-Muscle Invasive Bladder Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the TARA page.
See TARA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TARA catalysts and pipeline →